Event > Webinar >
Drug-induced liver injury assessment using adaptable liver microphysiological systems
Discover how Liver MPS address unmet DILI challenges – from cross‑species comparisons to evaluating cholestatic and complex mechanistic risks. Explore how MPS strengthen toxicology workflows, reduce translational risk, and improve confidence in human safety outcomes.
Predicting drug-induced liver injury (DILI) remains a persistent challenge in drug development. Complex, species-specific mechanisms and late-emerging toxicity can hinder preclinical safety assessment and reduce confidence in translational predictions. Advances in liver microphysiological systems (MPS) now offer more physiologically relevant models for evaluating hepatotoxic risk across species and development stages.
In this webinar, Emily Richardson will discuss key strategies for applying adaptable liver MPS across toxicology workflows, from early screening through mechanistic investigation of adverse liver events in humans.
Topics to be covered:
- Considerations for evaluating cholestatic DILI
- Use of Liver MPS to unlock complex and latent DILI effects
- Common challenges in predicting DILI across development stages
- Application of liver MPS for cross-species risk assessment
- Insights from comparative human and preclinical liver model studies
About the Presenter:
Dr. Emily Richardson
Dr. Emily Richardson is driving development of MPS for toxicology and safety assessment. She led the development of CN Bio’s Lung and Lung/Liver models for infectious disease research and inhaled therapeutics, and spearheaded multiple other collaborative and grant-funded programmes, published peer-reviewed papers, and contributed to advancing regulatory acceptance of Organ-on-a-chip.
Her work bridges complex cell biology and real-world drug discovery, informed by a PhD from the University of Leicester in 3D cell culture for metastatic lung cancer and a BSc in Biochemistry and Molecular Medicine degree from the University of Nottingham.